20-F: Pharvaris Deucrictibant Shows Strong Phase 3 Efficacy

Pharvaris N.V. reports positive pivotal Phase 3 data for deucrictibant IR capsule in HAE on-demand treatment, with plans for a U.S. NDA submission in H1 2026.

Summary

• Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing therapies for rare bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).
• The company's lead molecule, deucrictibant, is an oral, small-molecule bradykinin B2 receptor antagonist being developed in immediate-release (IR) capsule and extended-release (XR) tablet formulations.
• The pivotal Phase 3 RAPIDe-3 study for deucrictibant IR capsule (20 mg) for on-demand HAE treatment met its primary and all 11 key secondary efficacy endpoints with statistical significance, demonstrating rapid onset of symptom relief (1.28 hours), shorter time to End of Progression (17.47 minutes), and faster complete symptom resolution (11.95 hours) compared to placebo.
• Deucrictibant IR was well tolerated in RAPIDe-3, with no treatment-related serious adverse events or discontinuations due to adverse events.
• The Phase 2 CHAPTER-1 study for deucrictibant prophylaxis showed an 84.5% reduction in mean monthly HAE attack rate with 40 mg/day compared to placebo, supporting further development of the XR formulation.
• The FDA lifted clinical holds on deucrictibant IND applications for on-demand (June 2023) and prophylactic (January 2024) HAE treatment following review of a 26-week rodent toxicology study.
• Pharvaris initiated the global pivotal Phase 3 CHAPTER-3 study for deucrictibant XR tablet (40 mg/day) for HAE prophylaxis in December 2024, aiming to enroll approximately 81 participants.
• The CREAATE global pivotal Phase 3 study for prophylactic and on-demand treatment of AAE-C1INH attacks was initiated in October 2025.
• The company reported a net loss of €175.7 million for the year ended December 31, 2025, an increase from €134.2 million in 2024.
• Research and development expenses increased by 26% to €124.5 million in 2025, primarily due to increased clinical and personnel expenditure for Phase 3 studies.
• General and administrative expenses decreased by 4% to €45.3 million in 2025, mainly due to reclassifications and reductions in consulting and legal fees, offset by higher personnel costs.
• Cash and cash equivalents stood at €291.7 million as of December 31, 2025.
• The company raised €160.3 million in net proceeds from an underwritten offering of ordinary shares and pre-funded warrants in July 2025.
• Pharvaris wholly owns intellectual property covering deucrictibant, with patents expiring in November 2038 or later, and relies on trade secrets.
• The company has entered into a license agreement with BRAIN Biotech AG for its core intellectual property, with up to €8.0 million in aggregate potential milestone payments remaining outstanding, plus low to medium single-digit tiered royalties on net sales.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to the highly successful Phase 3 clinical trial results for deucrictibant IR, which met all primary and key secondary endpoints, and the lifting of all FDA clinical holds. These achievements significantly de-risk the lead product candidate and pave the way for a near-term NDA submission, despite ongoing operating losses typical for a development-stage biotech.

Positives

• The pivotal Phase 3 RAPIDe-3 study for deucrictibant IR capsule met its primary and all 11 key secondary efficacy endpoints with statistical significance for on-demand HAE treatment, demonstrating rapid and sustained symptom relief.
• Deucrictibant IR was well tolerated in RAPIDe-3, with no treatment-related serious adverse events or discontinuations, indicating a favorable safety profile.
• The Phase 2 CHAPTER-1 study showed an 84.5% reduction in mean monthly HAE attack rate with deucrictibant prophylaxis, providing strong proof-of-concept for the XR formulation.
• The FDA lifted clinical holds on both on-demand (June 2023) and prophylactic (January 2024) HAE IND applications, removing significant regulatory hurdles.
• Development of an extended-release (XR) tablet formulation for once-daily prophylactic dosing is progressing, aiming for improved convenience and consistent exposure.
• The company has a robust intellectual property portfolio, including U.S. and international patents covering deucrictibant composition-of-matter, formulations, and methods of use, with expirations in November 2038 or later.
• Pharvaris has a strong management team with deep expertise in the bradykinin B2 receptor pathway and rare disease drug development, including experience with FIRAZYR and TAKHZYRO.
• The company has a substantial cash and cash equivalents balance of €291.7 million as of December 31, 2025, providing liquidity for ongoing operations and development.

Negatives

• The company has a limited operating history, has generated no revenues to date, and incurred significant operating losses of €175.7 million in 2025, an increase of 31% from €134.2 million in 2024.
• Pharvaris is heavily dependent on additional funding to continue operations and commercialization, with no assurance that capital will be available on acceptable terms or at all.
• Foreign exchange fluctuations negatively affected financial condition, with a €10.3 million foreign exchange loss in 2025 due to U.S. dollar depreciation against the euro.
• The company relies on third-party CDMOs for manufacturing, posing risks of supply disruptions, quality issues, and increased costs.
• The market opportunities for product candidates may be smaller than anticipated, potentially lowering future revenue.
• There is no head-to-head comparison data of deucrictibant with icatibant or other competitors, which may limit comparative claims if approved.
• The company does not comply with all best practice provisions of the Dutch Corporate Governance Code, which may affect shareholder protection.

Risks

• Uncertainty in the outcome of interactions with regulatory authorities, including the FDA, and the ability to resolve issues in a timely manner.
• The expected timing, progress, or success of product candidates, especially XR, which is in late-stage global clinical trials, is not guaranteed.
• Inability to replicate efficacy and safety demonstrated in the CHAPTER-1 study in ongoing and future nonclinical studies and clinical trials.
• Risks arising from epidemic diseases and geopolitical instability (e.g., Russia-Ukraine conflict, Middle East conflict) which may adversely impact business, nonclinical studies, and clinical trials.
• The timing, costs, and other limitations involved in obtaining regulatory approval for IR and XR or any other future product candidates.
• Inability to market, commercialize, and achieve market acceptance for product candidates if approved.
• Dependence on third parties to perform critical activities related to research, nonclinical safety and toxicology studies, development, and manufacturing.
• Disruptions at the FDA and other government agencies could hinder timely review and approval.
• The expense, time, and uncertainty involved in the development and consistent manufacturing and supply of product candidates, some of which may never reach regulatory approval.
• Inability to raise capital when needed or on acceptable terms, potentially leading to delays, reductions, or termination of product development programs and insolvency.
• Raising additional capital may cause dilution to existing shareholders, restrict operations, or require relinquishing rights to product candidates or technologies.
• Clinical trials may not uncover all possible adverse effects that patients may experience.
• No assurance of obtaining or maintaining orphan drug status, which could impact market exclusivity.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Exposure to new legislation, regulatory proposals, and healthcare payor initiatives that may increase compliance costs and affect market access.
• Manufacturing issues could increase product and regulatory approval costs or delay commercialization.
• If product candidates achieve marketing approval, pricing at a significant premium over competitive generic products may hinder business strategy.
• Strict price and access controls imposed by governments and/or pricing authorities, especially in the European Union, may adversely affect future profitability.
• Uncertainty of insurance coverage and reimbursement status for newly approved products, limiting marketability and revenue generation.
• Exposure to costly and damaging liability claims from clinical testing or commercialization, with product liability insurance potentially not covering all damages.
• If third parties fail to perform as contractually required, development programs could be delayed.
• Dependence on key management and scientific personnel; inability to retain or recruit could harm the business.
• If BRAIN Biotech AG exercises remedies due to payment failures or material breach of the license agreement, it could materially and adversely affect the business.
• Inability to obtain and maintain patent or trade secret protection, or if the scope of protection is insufficient, competitors could commercialize similar products.
• Patents could be found invalid or unenforceable if challenged.
• Inability to protect or enforce intellectual property rights in all jurisdictions.
• Changes in patent law could diminish the value of patents.
• Confidentiality agreements may not prevent unauthorized disclosure of trade secrets.
• Infringement, misappropriation, or violation of third-party intellectual property rights could lead to increased costs or inability to commercialize.
• Intellectual property litigation could be expensive and distract personnel.
• Inability to obtain necessary rights to product candidates through acquisitions and licenses.
• Relationships with healthcare professionals and payors are subject to fraud and abuse laws; non-compliance could lead to penalties.
• Rapid technological change could make product candidates or technologies obsolete.
• Economic, political, regulatory, and other risks associated with international operations.
• Failure to meet projected development goals could delay commercialization and impact stock price.
• Exposure to environmental, health, and safety laws and regulations, leading to potential enforcement, liability, and expenses.
• Misconduct by employees, contractors, or partners could lead to regulatory noncompliance and adverse effects.
• The trading price of ordinary shares may be highly volatile.
• Concentrated ownership of ordinary shares by significant shareholders could conflict with other interests.
• Potential PFIC status could result in adverse U.S. federal income tax consequences to U.S. investors.
• Dutch and European insolvency laws may offer less protection than U.S. insolvency laws.
• Internal computer systems or those of contractors may fail or suffer security breaches.
• Strategic transactions could impact liquidity, increase expenses, and distract management.
• If securities or industry analysts publish inaccurate or unfavorable research, stock price and trading volume could decline.
• Requirements of being a public company may strain resources and divert management's attention.

Future Outlook

Pharvaris plans to submit a New Drug Application (NDA) with the U.S. FDA in the first half of 2026 for the on-demand treatment of acute HAE attacks. The company intends to advance deucrictibant XR tablets through clinical development as an extended-release prophylactic treatment for HAE, leveraging existing clinical data. There are also plans to expand deucrictibant's application to other bradykinin-mediated angioedema indications, including HAE with normal C1INH and AAE-C1INH, and to explore additional bradykinin-mediated diseases beyond angioedema. The company expects to independently commercialize deucrictibant IR and XR in the United States, establishing a focused commercialization and sales infrastructure in 2026.

Management Comments

• We believe deucrictibant has the potential to provide injectable-like efficacy with a well-tolerated profile and the convenience of an oral therapy for both the prophylactic and on-demand treatment of HAE attacks.
• With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.
• An oral prophylactic that could offer injectable-like efficacy, placebo-like tolerability, and the convenience of an oral, could potentially become a market leader in HAE.
• HAE patients need alternatives that better meet their objectives for ease of treatment, disease control, and improved quality of life.
• We anticipate that there will be strong interest in safe and effective, orally delivered, small-molecule treatments that can match or improve upon the efficacy profile of existing therapies.

Industry Context

StockSavvy.ai notes that the HAE treatment market is competitive, with global sales estimated at $2.7 billion in 2024 and a forecast growth to $4.7 billion by 2036. Pharvaris's deucrictibant, as a novel oral bradykinin B2 receptor antagonist, aims to differentiate itself by offering injectable-like efficacy with oral convenience, addressing a significant unmet need for non-injectable therapies. The success of RAPIDe-3 positions deucrictibant IR to potentially become a new standard of care for on-demand treatment, while the prophylactic XR formulation could challenge existing injectable market leaders like TAKHZYRO and DAWNZERA by offering a convenient oral alternative.

Comparison to Industry Standards

• Deucrictibant IR's rapid onset of symptom relief (1.28 hours) and complete symptom resolution (11.95 hours) in RAPIDe-3 are compelling, positioning it favorably against existing on-demand injectable therapies like icatibant (FIRAZYR) by offering oral convenience.
• The 84.5% reduction in mean monthly HAE attack rate with deucrictibant prophylaxis in CHAPTER-1 is comparable to the efficacy of approved injectables such as lanadelumab-flyo (TAKHZYRO) and donidalorsen (DAWNZERA), suggesting injectable-like efficacy with the added benefit of oral administration.
• Deucrictibant's placebo-like safety and tolerability profile observed across multiple clinical trials differentiates it from some existing therapies that may have more pronounced side effects or administration burdens.
• The strategy of offering both on-demand and prophylactic products with the same active ingredient (deucrictibant) provides a unique treatment flexibility for patients, particularly children and adolescents, which is not currently offered by competitors like Takeda's TAKHZYRO or BioCryst's ORLADEYO.
• Deucrictibant is described as a more potent inhibitor than icatibant, with the lowest dosage of any oral AE-BK on-demand treatment and a longer half-life, potentially offering a superior pharmacological profile.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings that arise in the ordinary course of business, but believes the outcome will not have a material adverse effect on its financial position.
• No material adverse effect on financial position from litigation during the period covered by the audited financial statements.

Related Party Transactions

• In June 2023, General Atlantic PH B.V., venBio Global Strategic Fund III, L.P., entities affiliated with Bain Capital Life Sciences Investors, LLC, Foresite Capital, and Venrock Healthcare Capital Partners purchased ordinary shares in a private placement.
• In December 2023, General Atlantic PH B.V. purchased pre-funded warrants in an underwritten offering, which were exercised in January 2024.
• In July 2025, the company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Leerink Partners, LLC, which involved the issuance and sale of ordinary shares and pre-funded warrants.
• The company engages GrayMatters Consulting BV, a management entity controlled by Dr. Lesage (Chief Early Development Officer), for key management services, with expenses of €0.7 million in 2025.
• Dr. Jochen Knolle, a former Chief Scientific Officer, received €0.5 million in 2023 under his consulting agreement and continues as a strategic advisor.
• The company has employment agreements with senior management and service contracts with non-executive directors, detailing compensation and other terms.

Stakeholder Impact

• Shareholders: Potential for significant value appreciation due to positive Phase 3 clinical trial results and upcoming NDA submission, but also dilution risk from future equity raises and volatility in share price. Rights may differ from U.S. corporations due to Dutch corporate law and DCGC deviations.
• Patients (HAE/AAE-C1INH): Potential for improved quality of life and convenience with novel oral on-demand and prophylactic treatments, addressing unmet medical needs.
• Employees: Continued growth and expansion of the company, but also intense competition for qualified personnel and potential for high turnover in the industry.
• Regulatory Authorities: Ongoing engagement and compliance with FDA, EMA, and other regulatory bodies for clinical trials, approvals, and post-marketing requirements.
• Third-party Payors: Potential for new products to be priced at a premium, but also subject to increasing pressure for cost-containment and reimbursement challenges.
• Suppliers/CDMOs: Continued reliance on third parties for manufacturing and clinical trial services, with risks related to supply chain disruptions and quality control.

Next Steps

• Submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute HAE attacks.
• Continue enrollment in the CHAPTER-3 global pivotal Phase 3 study of deucrictibant XR tablet for HAE prophylaxis.
• Continue open-label extension studies (RAPIDe-2 and CHAPTER-4) to collect long-term safety and efficacy data in HAE patients.
• Continue the CREAATE global pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks.
• Establish a focused commercialization and sales infrastructure in the United States in 2026.
• Evaluate independent commercialization and corporate partnerships for other geographies.
• Expand the range of bradykinin-mediated angioedema indications for deucrictibant.
• Identify additional disease areas and indications for portfolio expansion beyond angioedema, such as cardiovascular, allergy and immunology, or neurological diseases.

Key Dates

Recommendation

The filing presents highly positive and de-risking clinical data for deucrictibant, particularly the successful pivotal Phase 3 RAPIDe-3 study for on-demand HAE treatment, which met all primary and key secondary endpoints with statistical significance. The lifting of all FDA clinical holds further reduces regulatory uncertainty. While the company continues to incur significant losses, this is typical for a development-stage biopharmaceutical firm with a late-stage asset. The clear path to a U.S. NDA submission in H1 2026, coupled with promising prophylactic data and a strong cash position, indicates significant near-term catalysts and long-term commercial potential in a growing rare disease market. The oral formulation offers a compelling differentiation against existing injectable therapies, suggesting strong market adoption if approved.

Keywords

Hereditary Angioedema, HAE, Bradykinin B2 Receptor Antagonist, Deucrictibant, PHA121, PHVS416, PHVS719, Rare Disease, Clinical Trials, Phase 3, RAPIDe-3, CHAPTER-3, AAE-C1INH, Orphan Drug, Biopharmaceutical, SEC Filing, 20-F, Drug Development, Oral Therapy, Prophylaxis, On-demand Treatment